Screener
EBIT at other companies
Other financials
Where this comes from
Calculated from Supernus Pharmaceuticals’s reported figures.
Plus components not separately reported this period.
The source filing: Supernus Pharmaceuticals’s 10-Q, filed May 5, 2026. Open the filing →
- Filed
- May 5, 2026, 4:15 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001356576-26-000022
FAQ
- What is Supernus Pharmaceuticals's EBIT?
- Supernus Pharmaceuticals (SUPN) reported EBIT of -$8.33M in Q1 2026.
- How has Supernus Pharmaceuticals's EBIT changed year-over-year?
- Supernus Pharmaceuticals's EBIT increased by 18.8% year-over-year, from -$10.26M to -$8.33M.
- What is the long-term trend for Supernus Pharmaceuticals's EBIT?
- Over 4 years (2021 to 2025), Supernus Pharmaceuticals's EBIT has grown at a -7.8% compound annual growth rate (CAGR), from $86.03M to -$62.28M.
- What does EBIT mean?
- Earnings before interest and taxes — the profit from the business before financing cost and tax. Uses reported operating income where a company reports it; otherwise pre-tax income plus interest expense. Lets companies be compared on earning power independent of capital structure.
Ask your AI about Supernus Pharmaceuticals's ebit.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude